Trial Updates

Using machine learning predictions to design more efficient MS clinical trials 5:28
Using machine learning predictions to design more efficient MS clinical trials
David Li-Bland • 2 Mar 2022
SAkura: long-term safety and efficacy of satralizumab for NMOSD 1:27
SAkura: long-term safety and efficacy of satralizumab for NMOSD
Michael Levy • 25 Feb 2022
Biology or poor trial design…What underlies remyelination trial failures in MS? 4:50
Biology or poor trial design…What underlies remyelination trial failures in MS?
Gavin Giovannoni • 1 Mar 2022
Recent progress and future needs in NMOSD treatment 1:39
Recent progress and future needs in NMOSD treatment
Michael Levy • 25 Feb 2022
Key clinical trials of disease modifying therapies in Parkinson’s disease 2:12
Key clinical trials of disease modifying therapies in Parkinson’s disease
Fabrizio Stocchi • 18 Mar 2022
Phase II trial of ambroxol as a disease modifying therapy for Parkinson’s disease dementia 8:59
Phase II trial of ambroxol as a disease modifying therapy for Parkinson’s disease dementia
Stephen Pasternak • 16 Mar 2022
Investigating the impact of at-home training and tDCS on cognitive function in MS 1:44
Investigating the impact of at-home training and tDCS on cognitive function in MS
Leigh Charvet • 26 Feb 2022
Utilizing tDCS to improving hand dexterity in patients with MS 0:59
Utilizing tDCS to improving hand dexterity in patients with MS
Leigh Charvet • 26 Feb 2022
CLASSIC-MS: 8-10 year follow-up of ORACLE trial shows long-term efficacy of cladribine for MS 3:57
CLASSIC-MS: 8-10 year follow-up of ORACLE trial shows long-term efficacy of cladribine for MS
Gavin Giovannoni • 1 Mar 2022
COVID-19 outcomes in patients with relapsing MS receiving cladribine 2:22
COVID-19 outcomes in patients with relapsing MS receiving cladribine
Gavin Giovannoni • 1 Mar 2022
Environmental interactions in multiple sclerosis according to DRB1 hetero-homozygosity 4:10
Environmental interactions in multiple sclerosis according to DRB1 hetero-homozygosity
Lars Alfredsson • 25 Feb 2022
Factors affecting the risk of relapsing- and progressive-onset multiple sclerosis 3:32
Factors affecting the risk of relapsing- and progressive-onset multiple sclerosis
Lars Alfredsson • 25 Feb 2022
CanProCo: understanding factors related to progression in MS 1:23
CanProCo: understanding factors related to progression in MS
Jiwon Oh • 25 Feb 2022
Long-term safety and efficacy of tolebrutinib for relapsing multiple sclerosis 2:22
Long-term safety and efficacy of tolebrutinib for relapsing multiple sclerosis
Jiwon Oh • 25 Feb 2022
Ozanimod: long-term safety and efficacy in relapsing MS 1:09
Ozanimod: long-term safety and efficacy in relapsing MS
Jeffrey Cohen • 24 Feb 2022
cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGAD 1:32
cosMOG: anti-FcRn agent rozanolixizumab for relapse prevention in MOGAD
Michael Levy • 25 Feb 2022
The content of VJNeurology is intended for healthcare professionals